Neuren Pharmaceuticals

Date of inclusion: 10 March 2021
Share price on inclusion: $1.255

Date of exclusion: 25 August 2021
Share price on exclusion: $2.24

Neuren has performed well since we included it in Marc and Stuart’s Top Picks list on 10 March 2021, rising 78.5%. We like the potential of this company to revolutionise the treatment of rare neurological disorders with its trofinenide drug. The Phase 2 data in Rett Ryndrome looked good and the company secured Acadia Pharmaceuticals (Nasdaq: ACAD) as a great North American partner in 2018.

Why is Neuren coming off our Top Pick list?
Acadia’s Phase 3 is expected to read out data before the end of 2021. Phase 3 studies, however, don’t always go to plan.

After an almost 80% gain on NEU, we think it’s better to realise some gains on this one ahead of that data readout.